RAFAEL HOLDINGS, INC. Capital Expenditures Incurred but Not yet Paid
RAFAEL HOLDINGS, INC. (RFL) reported Capital Expenditures Incurred but Not yet Paid of $5.75 million for the 12-month period ending 2024-07-31, per its 10-K filed 2025-10-29.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2025-10-29
- RAFAEL HOLDINGS, INC. capital expenditures incurred but not yet paid for the quarter ending 2024-07-31 was $0.00.
- RAFAEL HOLDINGS, INC. capital expenditures incurred but not yet paid for fiscal 2024 was $5.75M.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|
| 2024-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29 | $5.75M 10-K · filed 2025-10-29 | |
| 2024-04-30 | $5.75M 10-Q · filed 2025-06-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |